Phase I Trial of TURALIO(R) (Pexidartinib, PLX3397) in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) and Tenosynovial Giant Cell Tumor ...

Inclusion Criteria

• •Diagnosis:
• •* Individuals must have recurrent or refractory solid tumors or acute leukemia (limited to AML or ALL) or have been intolerant of prior therapies, confirmed by the Laboratory of Pathology, NCI, e.g., solid tumors including rhabdomyosarcoma, Ewing sarcoma, soft tissue sarcomas. These may include primary neoplasms of the central nervous system, such as high-grade (WHO grade III-IV) glioma. Individuals with diffuse intrinsic pontine glioma (DIPG) or optic pathway glioma are exempt from histologic verification. For DIPG typical MRI findings must be present which include hypo- or isointense on T1-weighted imaging, hyperintense on FLAIR or T2-weighted imaging, epicenter in the pons in the face of a typical clinical presentation. Optic pathway gliomas are located in the optic pathway and are typically hypo- or iso-intense on T1 and hyperintense on T2-weighted images.
• •* In addition, individuals with NF1 and with malignant peripheral nerve sheath tumor (MPNST).
• •* Individuals must have relapsed after or be refractory to effective standard therapies. There are no limits on number of prior therapeutic regimens.
• •Disease status: Individuals with refractory solid tumors including patients with NF1 and MPNST must have evaluable disease, patients with leukemia must have measurable or evaluable disease at the time of enrollment, which may include any evidence of disease including minimal residual disease detected by flow cytometry.
• •Age \>= 3 and \<= 35 years of age (must have BSA \>= 0.55 m\^2):
• •Ability of subject or Legally Authorized Representative \[LAR\] (the parent/guardian if subject is a minor) to understand and the willingness to sign a written informed consent document.
• •Individuals must be able to swallow capsules.
• •Performance Status: Karnofsky \>= 50% for patients \> 16 years of age and Lansky \>= 50% for patients \<= 16 years of age. Individuals who are wheelchair bound because of paralysis will be considered "ambulatory" when they are up in their wheelchair. Individuals have to be able to travel to the NIH for evaluations.
• •Prior therapy:
• •Individuals must have fully recovered (to Grade 1) from the acute toxic effects of all prior anti-cancer therapy.
• •Myelosuppressive chemotherapy: At least 21 days after the last dose of myelosuppressive chemotherapy (42 days if prior nitrosourea).
• •Biologic (anti-neoplastic agent): At least 7 days after the last dose of a biologic agent. For agents that have known adverse events occurring beyond 7 days after administration, this period must be extended beyond the time during which adverse events are known to occur. The duration of this interval must be discussed with the study chair.
• •Immunotherapy: At least 42 days after the completion of any type of immunotherapy, e.g. tumor vaccines.
• •Monoclonal antibodies: At least 3 half-lives of the antibody after the last dose of a monoclonal antibody.
• •XRT: At least 7 days after local palliative XRT (small port); At least 150 days must have elapsed if prior TBI or if \>= 50% radiation of pelvis; \>= 14 days from whole brain radiation, craniospinal radiation, or targeted radiation to CNS tumors. At least 42 days must have elapsed if other substantial BM radiation.
• •HSCT: \>= 56 days from stem cell transplant with no evidence of active graft vs. host disease; must be off immunosuppressive therapy for at least 4 weeks and have no active graft-versus-host disease (GVHD) at the time of entry onto this trial.
• •Surgery: \>= 14 days from surgery
• •Others: \>= 7 days from last dose of short active hematopoietic growth factors, i.e. filgrastim, \>= 14 days for long-acting, i.e. pegfilgrastim.
• •-Individual must have adequate hematologic, hepatic, and renal function, defined by:
• •Absolute neutrophil count \>= 1.5 x 10\^9/L
• •Hemoglobin \> 10 g/dL
• •Platelet count \>= 100 x 10\^9/L
• •AST and ALT \<= upper limit of normal (ULN)
• •TBil and DBil \<= ULN with an exception of patients with confirmed Gilbert's syndrome. For patients with confirmed Gilberts syndrome, the TBil should be \<= 1.5 x ULN
• •Serum creatinine \<= 1.5 x ULN
• •Exceptions:
• •* Cytopenias due to underlying disease (i.e. potentially reversible with anti-neoplastic therapy); A subject will not be excluded because of cytopenia due to disease, based on the results of bone marrow studies.
• •* Known active or chronic human immunodeficiency virus (HIV) or hepatitis C virus (HCV) infection, or positive hepatitis B (Hep B) surface antigen. Prior hepatitis infection that has been treated with highly effective therapy with no evidence of residual infection and with normal liver function (ALT, AST, total and direct bilirubin \<= ULN) is allowed.
• •* Hepatobiliary diseases including biliary tract diseases, autoimmune hepatitis, inflammation, fibrosis, cirrhosis of liver caused by viral, alcohol, or genetic reasons. Gilbert's disease is allowed if TBil is \<= 1.5 x ULN.
• •* Cardiac ejection fraction \>= 50%, and QTcF \< 450 ms (male) or \<470 ms (female) on ECG at Baseline. (Fridericia's Formula: QTcF = (QT)/RR0.33)
• •* Contraception: Women of child-bearing potential must agree to use an effective method of birth control during treatment and for 1 month after receiving their last dose of study drug. Fertile men must also agree to use an acceptable method of birth control while on study drug and for at least one month after last dose.
• •Drugs that strongly inhibit or potentiate CYP3A4, which includes CYP3A4 inducer, UGT inhibitors and acid reducing agents and avoid concomitant use of PPIs:
• •* Individuals who have received these drugs within 14 days or within 5 half-lives of the drug (whichever is longer) prior to study initiation will be excluded.